Genome-based and transcriptome-based molecular classification of breast cancer

Current Opinion in Oncology

Volumn 23, Issue 1, 2011, Pages 93-99

  Bièche, Ivan ^a   Lidereau, Rosette ^a  

^a INSTITUT CURIE   (France)

Author keywords

Breast cancer; Classification; Epigenetic alterations; Genetic alterations

Indexed keywords

AURORA A KINASE; B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 1; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; K RAS PROTEIN; LAPATINIB; MRE11 PROTEIN; MYC PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2D; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MCL 1; PROTEIN P53; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR PBX1; TRANSCRIPTOME; TRASTUZUMAB; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNINDEXED DRUG; UVOMORULIN; WNT1 PROTEIN;

ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER PATIENT; COMPARATIVE GENOMIC HYBRIDIZATION; CPG ISLAND; EPIGENETICS; GENE AMPLIFICATION; GENE EXPRESSION; GENE SEQUENCE; HUMAN; NONHUMAN; ONCOGENE H RAS; ONCOGENE N RAS; POINT MUTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

BREAST NEOPLASMS; EPIGENOMICS; FEMALE; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; POINT MUTATION;

EID: 79851510952     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283412ee0     Document Type: Article

References (61)

1. Tirkkonen M, Tanner M, Karhu R, et al. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 1998; 21:177-184. (Pubitemid 28136434)
2. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003; 3:51-62. (Pubitemid 37443890)
3. Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006; 10:529-541. (Pubitemid 44854748)
4. Leary RJ, Lin JC, Cummins J, et al. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A 2008; 105:16224-16229.
5. Yu JS, Koujak S, Nagase S, et al. PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene 2008; 27:4657-4665.
6. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copynumber alteration across human cancers. Nature 2010; 463:899-905.
7. Berx G, Cleton-Jansen AM, Strumane K, et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996; 13:1919-1925. (Pubitemid 26397451)
8. Usary J, Llaca V, Karaca G, et al. Mutation of GATA3 in human breast tumors. Oncogene 2004; 23:7669-7678. (Pubitemid 39424925)
9. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314:268-274. (Pubitemid 44571966)
10. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318:1108-1113. (Pubitemid 350134889)
11. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005; 7:561-573. (Pubitemid 40799249)
12. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesench- ymal transition and stem cell characteristics. Cancer Res 2009; 69:4116-4124.
13. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12:395-402. (Pubitemid 47539306)
14. Eichhorn PJ, Gili M, Scaltriti M, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008; 68:9221-9230.
15. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007; 448:439-444. (Pubitemid 47123510)
16. Troxell ML, Levine J, Beadling C, et al. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. Mod Pathol 2010; 23:27-37.
17. Lauring J, Cosgrove DP, Fontana S, et al. Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. Oncogene 2010; 29:2337-2345.
18. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005; 65:2554-2559. (Pubitemid 40490050)
19. Arnold JM, Choong DY, Thompson ER, et al. Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors. Breast Cancer Res Treat 2010; 119:491-496.
20. Stephens P, Edkins S, Davies H, et al. Ascreen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 2005; 37:590-592. (Pubitemid 40770413)
21. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39:347-351. (Pubitemid 46328493)
22. Theodorou V, Kimm MA, Boer M, et al. MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nat Genet 2007; 39:759-769. (Pubitemid 46848585)
23. Rabbitts TH. Commonality but diversity in cancer gene fusions. Cell 2009; 137:391-395.
24. Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002; 2:367-376. (Pubitemid 41039103)
25. Laé M, Fréneaux P, Sastre-Garau X, et al. Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod Pathol 2009; 22:291-298.
26. Zhao Q, Caballero OL, Levy S, et al. Transcriptome-guided characterization of genomic rearrangements in a breastcancer cell line. Proc Natl Acad Sci U S A 2009; 106:1886-1891.
27. Hampton OA, Den Hollander P, Miller CA, et al. A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution ofa cancer genome. Genome Res 2009; 19:167-177.
28. Stephens PJ, McBride DJ, Lin ML, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009; 462:1005-1010.
29. Callahan R, Smith GH. MMTV-induced mammary tumorigenesis: gene discovery, progression to malignancy and cellular pathways. Oncogene 2000; 19:992-1001. (Pubitemid 30153782)
30. Wang Y, Holland JF, Bleiweiss IJ, et al. Detection ofmammary tumor virus env gene-like sequences in human breast cancer. Cancer Res 1995; 55:5173-5179.
31. Lawson JS, Glenn WK, Salmons B, et al. Mouse mammary tumor virus-like sequences in human breast cancer. Cancer Res 2010; 70:3576-3585.
32. Liu B, Wang Y, Melana SM, et al. Identification of a proviral structure in human breast cancer. Cancer Res 2001; 61:1754-1759. (Pubitemid 34292615)
33. Wang-Johanning F, Frost AR, Jian B, et al. Quantitation of HERV-K env gene expression and splicing in human breast cancer. Oncogene 2003; 22:1528-1535. (Pubitemid 36390602)
34. Wang-Johanning F, Radvanyi L, Rycaj K, et al. Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients. Cancer Res 2008; 68:5869-5877.
35. Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009; 461:809-813.
36. Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464:999-1005.
37. Liu TX, Becker MW, Jelinek J, et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med 2007; 13:78-83. (Pubitemid 46067389)
38. International Cancer Genome Consortium. International network of cancer genome projects. Nature 2010; 464:993-998.
39. Paro R, Lee JT. Extending the frontiers of epigenetic regulation. Curr Opin Genet Dev 2010; 20:107-109.
40. Lo PK, Sukumar S. Epigenomics and breast cancer. Pharmacogenomics 2008; 9:1879-1902.
41. Ordway JM, Budiman MA, Korshunova Y, et al. Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS One 2007; 2:e1314.
42. Flusberg BA, Webster DR, Lee JH, et al. Direct detection of DNA methylation during single-molecule, real-time sequencing. Nat Methods 2010; 7:461-465.
43. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65:7065-7070. (Pubitemid 41161233)
44. O'Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 2010; 12:201.
45. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857-866. (Pubitemid 44629897)
46. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449:682-688. (Pubitemid 47552092)
47. Ma L, Reinhardt F, Pan E, et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010; 28:341-347.
48. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009; 136:629-641.
49. Mercer TR, Dinger ME, Mattick JS. Long noncoding RNAs: insights into functions. Nat Rev Genet 2009; 10:155-159.
50. Gupta RA, Shah N, Wang KC, et al. Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464:1071-1076.
51. Yap KL, Li S, Muñoz-Cabello AM, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 2010; 38:662-674.
52. Pasmant E, Laurendeau I, Héron D, et al. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 2007; 67: 3963-3969. (Pubitemid 46762186)
53. Turnbull C, Ahmed S, Morrison J, et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 2010; 42: 504-507.
54. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
55. Charafe-Jauffret E, Ginestier C, Lovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009; 69:1302-1313.
56. DiMeo TA, Anderson K, Phadke P, et al. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res 2009; 69:5364-5373.
57. Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008; 68:3108-3114.
58. Driouch K, Bonin F, Sin S, et al. A six-gene signature predicting breast cancerlung metastasis. Reply. Cancer Res 2009; 69:9507-9511.
59. Rhodes DR, Ateeq B, Cao Q, et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci U S A 2009; 106:10284-10289.
60. Li J, Orlandi R, White CN, et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 2005; 51:2229-2235. (Pubitemid 41692564)
61. Hudelist G, Pacher-Zavisin M, Singer CF, et al. Use of high-throughput protein array for profiling of differentially expressed proteins in normal and malignant breast tissue. Breast Cancer Res Treat 2004; 86:281-291. (Pubitemid 39089109)